A drug already used for achondroplasia sped up growth in a related skeletal condition

A drug already approved for achondroplasia increased the rate at which children with a related skeletal condition grew, in a phase 3 trial published in NEJM Evidence [s1]. The condition, hypochondroplasia, has no targeted treatment, so a positive trial is a genuine first — but the result is about how fast children grew over one year, not about how tall they will end up [s1].

Hypochondroplasia is caused by variants in the fibroblast growth factor receptor 3 gene (FGFR3), the same receptor implicated in achondroplasia, and produces disproportionate short stature along with a range of clinical features [s1]. Vosoritide is a laboratory-made analogue of C-type natriuretic peptide, a signalling molecule that counteracts the growth-restraining effect of an overactive FGFR3; it is already licensed for achondroplasia and was being tested here in the adjacent disorder [s1].

The trial

Children aged 3 to under 18 with hypochondroplasia were randomly assigned to a once-daily injection under the skin of either vosoritide or placebo for 52 weeks, dosed by weight band [s1]. The primary endpoint was the change from baseline in annualised growth velocity — how many centimetres a child grows in a year — at week 52, compared with placebo [s1]. A total of 81 participants were assigned, 41 to vosoritide and 40 to placebo [s1].

At 52 weeks, the least-squares mean change from baseline in annualised growth velocity was 1.95 cm/year with vosoritide, against −0.39 cm/year with placebo — a difference of 2.33 cm/year (95% CI, 1.85 to 2.82; two-sided P<0.0001) [s1]. The trial was structured to guard against false positives: the primary endpoint and six key secondary endpoints were tested in a fixed hierarchy, controlling the error rate at a one-sided 0.025 level, equivalent to the conventional two-sided 0.05 [s1]. That matters because trials with many secondary measures can otherwise turn chance findings into apparent wins; here the statistical plan was set to prevent it.

On safety, most participants had at least one adverse event, 87.8% on vosoritide and 72.5% on placebo, but there were no grade 3 or higher adverse events, none that led to stopping treatment, and no deaths over the year [s1].

What a growth-velocity endpoint does and does not tell you

Growth velocity is the standard endpoint in these trials because it reads out within a year, but it is a surrogate: it measures the speed of growth over 52 weeks, not adult height, and not any of the medical complications — spinal, neurological, ear-related — that make skeletal dysplasias more than a question of stature. A faster growth rate in year one need not translate into a proportional gain in final height, because growth velocity can wane and because children grow for many years after a trial ends. The same caution applies to other rare-disease drugs cleared on short-term markers, such as elamipretide for Barth syndrome, where the endpoint that earns approval is not always the outcome families care about most.

That does not diminish the finding. For a condition with nothing targeted to offer, a clear, replicated-mechanism effect on growth, with no severe adverse events over a year, is a real result [s1]. It does mean the honest framing is narrow: vosoritide increased how fast these children grew over 52 weeks. Whether that becomes a durable difference in height or in the harder outcomes of hypochondroplasia is a longer question, and one this trial was not designed to close. The trial was funded by the manufacturer, BioMarin [s1].